Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 4/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HRH2 | P25021 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201910 | 0.80 | NPC1 (0.42) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL5203370 | 0.80 | HRH2 (0.47) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL4860169 | 0.77 | MAPT (0.40) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL5203731 | 0.75 | PDE2A (0.41) | HSD11B1ALDH1A1CNR1 | |
| SCHEMBL5204952 | 0.74 | HRH2 (0.55) | ALDH1A1HRH2CNR1 | |
| SCHEMBL5202530 | 0.73 | ALDH1A1 (0.42) | CREBBPALDH1A1CNR1GAA | |
| SCHEMBL4852959 | 0.73 | SMN1; SMN2 (0.53) | CREBBPALDH1A1HRH2POLB | |
| SCHEMBL5202510 | 0.69 | HSD11B1 (0.55) | HSD11B1ALDH1A1HRH2CNR1 | |
| SCHEMBL5204533 | 0.69 | ALDH1A1 (0.46) | HSD11B1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5203151 | 0.69 | ALDH1A1 (0.50) | CREBBPALDH1A1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | claimed |
| US-7368470-B2 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | OPRD1, OPRK1, TPH1 | CREBBP 325/4885HSD11B1 1144/4885HDAC3 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.